dacarbazine and bortezomib

dacarbazine has been researched along with bortezomib in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (30.00)29.6817
2010's14 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; PĆ©deboscq, S; Pometan, JP1
Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M1
Schiff, D; van den Bent, MJ; Wen, PY1
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y1
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM1
Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M1
Bota, DA; Gong, X; Linskey, ME; Schwartz, PH1
Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P1
Chim, CS; Choi, PT; Lee, WK1
Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE1
Befani, CD; Hatzidaki, E; Liakos, P; Papandreou, CN; Vlachostergios, PJ1
Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J1
Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y1
Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W1
Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J1

Reviews

2 review(s) available for dacarbazine and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration

2009

Trials

5 trial(s) available for dacarbazine and bortezomib

ArticleYear
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
    International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome

2009
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome

2010
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult

2012
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult

2013
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
    Journal of neuro-oncology, 2016, Volume: 129, Issue:1

    Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Temozolomide; Treatment Outcome

2016

Other Studies

13 other study(ies) available for dacarbazine and bortezomib

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide

2004
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles

2008
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide

2010
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
    Clinical neurosurgery, 2009, Volume: 56

    Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured

2009
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Neurology, 2011, Mar-29, Volume: 76, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide

2011
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Annals of hematology, 2013, Volume: 92, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine

2013
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-akt; Pyrazines; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53

2013
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Journal of neurosurgery, 2013, Volume: 119, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2013
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Molecular medicine reports, 2015, Volume: 12, Issue:2

    Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Bortezomib; Cell Survival; Dacarbazine; Disulfiram; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nestin; Peptides; Pituitary Neoplasms; Primary Cell Culture; Proteasome Inhibitors; Proteolysis; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays

2015
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
    The Journal of investigative dermatology, 2016, Volume: 136, Issue:7

    Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Skin Neoplasms; Temozolomide

2016